This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

BioNTech-CureVac deal has received all necessary antitrust clearances

( October 21, 2025, 21:02 GMT | Official Statement) -- MLex Summary: Pharma companies BioNTech and CureVac "have, as of October 14, 2025, obtained all relevant non-U.S. antitrust approvals," and their deal was cleared by US antitrust law enforcers in August, according to a filing submitted to the US Securities and Exchange Commission. The firms received EU foreign investment clearance on Oct. 10, the SEC filing said.See SEC filing excerpt below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login